The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population
暂无分享,去创建一个
R. Fanin | G. Pizzolo | M. Krampera | E. Tacconelli | M. Tiribelli | M. Bonifacio | M. Ruggeri | G. Semenzato | M. Trawinska | E. Abruzzese | D. Damiani | G. Binotto | L. Scaffidi | Maria Vittoria Dubbini | E. di Bona | M. Cordioli | Mariella Lo Schirico | M. Miggiano | I. Tanasi | Vanessa Velotta | G. Ceccarelli | Elisabetta Pierdomenico
[1] A. E. Eşkazan,et al. COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single Center Survey from Turkey. , 2020, Turkish journal of haematology : official journal of Turkish Society of Haematology.
[2] C. de Ciuceis,et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID‐19 , 2020, Cancer.
[3] L. Baglietto,et al. Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2 , 2020, Frontiers in Oncology.
[4] S. Başcı,et al. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[5] G. Corrao,et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.
[6] C. Laprise,et al. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status , 2020, Journal of Infection and Public Health.
[7] P. Westerweel,et al. Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study , 2020, Leukemia.
[8] R. Foà,et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey , 2020, Leukemia.
[9] Q. Jiang,et al. COVID-19 in persons with chronic myeloid leukaemia , 2020, Leukemia.
[10] F. Pane,et al. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection , 2020, Mediterranean journal of hematology and infectious diseases.
[11] Paolo Giudici,et al. The Covid-19 pandemic in Italy , 2020 .
[12] M. Krampera,et al. Management of Chronic Myeloid Leukemia in Advanced Phase , 2019, Front. Oncol..
[13] Martin C. Müller,et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. , 2018, Blood.
[14] M. Frieman,et al. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors , 2018, bioRxiv.
[15] T. Brümmendorf,et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Amy Hughes,et al. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission , 2017, Front. Immunol..
[17] Francisco Cervantes,et al. Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia , 2017, The New England journal of medicine.
[18] M. Frieman,et al. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion , 2016, Journal of Virology.
[19] M. Baccarani,et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] I. Flinn,et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial , 2016, Leukemia.
[21] E. Letsiou,et al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. , 2015, American journal of physiology. Lung cellular and molecular physiology.